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Allogeneic hematopoietic cell transplantation (AHCT) remains a potentially curative treat-ment modality for a variety of malignant and 
benign hematological disorders. The cellular compo-
sition of the donor grafts can affect clinical outcomes 
following AHCT. In myeloablative AHCT using bone 
marrow as a graft source, a clear association between 
higher CD34+ cell dose and improved survival has 
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BACKGROUND AND OBJECTIVES: Understanding the effect of cellular graft composition on allogeneic he-
matopoietic cell transplantation (AHCT) outcomes is an area of great interest. The objective of the study was 
to analyze the correlation between transplant-related outcomes and administered CD34+, CD3+, CD4+ and 
CD8+ cell doses in patients who had undergone peripheral blood, AHCT and received either in vivo T-cell de-
pleted or T-cell replete allografts. 
DESIGN AND SETTING: Comparison of consecutive patients who underwent peripheral blood AHCT in our 
institution between January 2003 and December 2009. 
PATIENTS AND METHODS: The cohort of 149 patients was divided into two groups; non T-cell depleted (NTCD) 
(n=54) and T-cell depleted (TCD) (n=95). Study endpoints were overall survival (OS), progression free survival 
(PFS), engraftment kinetics (neutrophil and platelet recovery), incidence of acute graft versus host disease (acute 
GVHD), chronic GVHD, non relapse mortality (NRM) and disease relapse.  
RESULTS: Multivariate analysis showed that higher infused CD34+ cell dose improved OS (relative risk 0.58, 
95% CI 0.34-0.98, P=.04), PFS (relative risk 0.59, 95% CI 0.35-1.00, P=.05) and NRM (relative risk 0.49, 95% 
CI 0.24-0.99, P=.048) in the TCD group. By multivariate analysis, there was no difference in engraftment, grades 
II-IV acute GVHD, extensive chronic GVHD and relapse in the two groups relative to the infused cell doses. 
There was a trend towards improved OS (relative risk 0.54, 95% CI 0.29-1.01, P=.05) with higher CD3+ cell 
dose in the TCD group. 
CONCLUSION: Our findings suggest that higher CD34+ cell dose imparts survival benefit only to in vivo TCD 
peripheral blood AHCT recipients.
been reported.1,2 Similarly, in the setting of peripheral 
blood AHCT, higher infused CD34+ cell doses have 
been shown to be associated with early neutrophil 
and platelet engraftment3-5 and improved survival5-9 in 
some but not all studies.10 The correlation of higher 
infused CD34+ doses with graft-versus-host disease 
(GVHD) in patients undergoing peripheral blood 
AHCT is even more controversial with some reports 
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showing increased incidence of grades II-IV acute 
GVHD11,12 and extensive chronic GVHD,4,9 while 
others report no such correlation.5,10 Similarly the cor-
relation between CD3+, CD4+ and CD8+ cell doses 
and GVHD has been discrepant with many reports 
suggesting no association.4,10,13,14 
Even though the influence of cellular composition of 
the infused allografts on transplantation outcomes has 
been the subject of many previous studies, there is pau-
city of data on the relative importance of cellular compo-
sition of the infused allograft on the transplantation out-
comes of patients undergoing peripheral blood AHCT 
with in vivo T-cell depletion compared to patients re-
ceiving T-cell replete allografts. A recent report has sug-
gested a survival benefit with higher infused CD34+ 
and CD3+ cell doses in pediatric patients undergoing 
AHCT with in vivo TCD.15 We report the impact of 
cellular graft composition on transplantation outcomes 
of adult patients who underwent T-cell depleted periph-
eral blood AHCT compared to patients who underwent 
T-cell replete peripheral blood AHCT. 
METHODS
The patient cohort included 149 consecutive patients 
who underwent granulocyte-colony stimulating fac-
tor (G-CSF) mobilized peripheral blood AHCT be-
tween January 2003 through December 2009 at our 
transplant center, who received either myeloablative 
(MA) (n=114) or non-myeloablative/reduced inten-
sity conditioning (NMA/RIC) (n=35) regimens. The 
patient population was divided in two groups based 
on whether they received in vivo T-cell depletion; non 
T-cell depleted (NTCD group) and T-cell depleted 
(TCD group). Sixty-three percent (n=95) received 
in vivo T-cell depletion with alemtuzumab (n=39) 
(Campath, Genzyme, Massachusetts, USA) or rab-
bit antithymocyte globulin (ATG) (Thymoglobulin, 
Genzyme) (n=52). Four patients with aplastic ane-
mia received equine ATG 30 mg/kg (Atgam, Pfizer). 
High-resolution human leukocyte antigen (HLA) typ-
ing was done at the allele level for class-I (HLA-A, -B, 
-C) and class II (HLA-DRB1) molecules as described 
before.16 Patients with 8/8 allele level match for HLA -
A, -B, -C and -DRB1 with their respective donors were 
considered a full match.17 The study was approved by 
the Institutional Review Board and Scientific Review 
Committee at our institution.
Determination of CD34+, CD3+, CD4+ and 
CD8+ cell doses was performed at the West Virginia 
University Flow Cytometry Laboratory (Morgantown, 
West Virginia). The BD FACSCanto II flow cytom-
eter, Becton Dickinson (San Jose, California) was used 
for all analyses. Red blood cell (RBC) lysed and washed 
samples were used for CD34+ enumeration with phy-
coerythrin (PE) labeled, 8G12 clone, immunoglobulin 
(Ig) G1 (Becton Dickinson, San Jose, California) based 
on International Society of Hematotherapy and Graft 
Engineering guidelines.18 An unwashed but RBC lysed 
sample was used to count CD3+, CD4+ and CD8+ 
cell doses. Four-color direct immunofluorescence re-
agent was used; BD MultiTEST™ fluoresein isothiocy-
anate (FITC)-labeled CD3, clone SK7; allophycocya-
nin (APC)-labeled CD4, clone SK3; PE-labeled CD8, 
clone SK1; peridinin chlorophyll protein (PerCP)-la-
beled CD45, clone 2D1 (Becton Dickinson, San Jose, 
California). Used in conjunction with Trucount tubes, 
the absolute numbers of CD3+, CD4+ and CD8 + 
was calculated using the BD MultiSET software 
(Becton Dickinson, San Jose, California). 
The study endpoints included engraftment, acute 
and chronic GVHD, relapse rate, nonrelapse mortal-
ity (NRM), overall survival (OS) and progression-free 
survival (PFS). Neutrophil engraftment was defined as 
days to an absolute neutrophil count (ANC) ≥0.5×109/
L for 3 consecutive days post-transplantation nadir and 
platelet engraftment as days to platelet count ≥20× 
109/L for 7 consecutive days without platelet transfu-
sion.19 Acute and chronic GVHD were graded using 
the standard criteria.20-23 All patients who successfully 
engrafted neutrophils were considered evaluable for 
acute GVHD. Patients surviving at least 100 days post 
transplantation were considered evaluable for chronic 
GVHD. OS was defined as the time to death due to 
any cause from the date of transplant. Surviving patients 
were censored at time of last follow up. Death, disease 
relapse and/or progression were considered events for 
PFS. NRM was defined as death from any cause other 
than disease progression or relapse.
The patient population was divided into NTCD 
or TCD groups. The cell doses of CD34+, CD3+, 
CD4+ and CD8+ in the NTCD and TCD groups 
were dichotomized as ≥ and <50th percentile based 
on median values.8,15 Baseline categorical variables for 
NTCD and TCD groups were compared by using the 
chi-square test or Fisher exact test, as appropriate; 
while continuous variables were compared using the 
t-test. All P values are two sided. OS and PFS were 
estimated using the Kaplan-Meier method and differ-
ences between the patient groups analyzed with the 
log-rank test. Cumulative incidence was estimated for 
NRM and relapse rate, with relapse as a competing risk 
for the former and death in remission for the latter. The 
Gray test was used to assess the difference between var-
ious subgroups for NRM and relapse rate.24 A propor-
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tional hazards model was created to assess the impact 
of infused cell doses on engraftment, acute GVHD, 
chronic GVHD, NRM, relapse, PFS and OS initially 
measured by univariate analysis. Multivariate logistic 
regression analysis was constructed for variables show-
ing significance on univariate analysis (P<0.1). All sta-
tistical analyses were performed with JMP-version 9, 
SAS Institute Inc., Cary, NC. P-values based on the 
Gray test were calculated using R-project version 2.8.1 
(The R Foundation for Statistical Computing, 2008).
RESULTS
The baseline patient characteristics are detailed in 
Table 1. All patients received G-CSF mobilized pe-
ripheral blood allografts. The TCD and NTCD 
groups were matched for median patient age (50 years 
and 48 years respectively; P=.32) and sex (P=1.0). As 
expected, notable differences were present at baseline 
among patients receiving a T-cell depleted vs a T-cell 
replete allograft. All patients with chronic myeloid leu-
kemia in first chronic phase, acute myeloid leukemia 
and acute lymphoblastic leukemia in first complete re-
mission and myelodysplastic syndrome with refractory 
anemia and refractory anemia with ringed sideroblasts 
were considered standard-risk, while all remaining pa-
tients were considered high-risk for relapse as defined 
previously.25,26 The intensity of the conditioning regi-
mens was defined using the working group recommen-
dations27 and the two groups were matched for MA 
versus NMA/RIC regimens (P=.17). There was no 
difference between the NTCD and TCD groups with 
regards to HLA-mismatched transplants (P=.29). 
Among those receiving HLA identical transplants 
more patients in the TCD group received allografts 
from unrelated donors (URD) (P<.01).
The median infused CD34+ cell dose was 5.8×106/
kg patient weight (PW); range 1.2-16. Median cell 
doses for CD3+, CD4+ and CD8+ cells were 30.8× 
107/kg PW (4.5-100.8), 18.7×107/kg PW (1.9-63) 
and 11.3×107/kg PW (0.8-52.4), respectively. Patients 
in the TCD group received a higher CD34+ cell dose 
(median; 6.2×106/Kg PW versus 5.4×106/Kg PW, 
P=.008). There was no difference in the CD3+, CD4+ 
and CD8+ cell doses between the groups (Table 2). 
One hundred and thirty-eight patients had success-
ful neutrophil engraftment after posttransplant nadir. 
Seven patients never achieved ANC ≥0.5×109/L, con-
sidered primary engraftment failure 28 and 4 patients 
who received NMA conditioning had a nadir above the 
threshold. Median time to neutrophil engraftment in 
the NTCD and TCD groups was 16 and 15 days, re-
spectively (mean NTCD 15.8 days, 95%CI 14.7-16.8 
and mean TCD 15.9 days, 95%CI 15.2-16.7); P=.78). 
In the TCD group, univariate analysis showed a trend 
toward early neutrophil engraftment with higher 
CD34+ cell dose (15.4 vs. 16.8 days, P=.08), however 
there was no correlation between CD3+, CD4+ and 
Table 1. Baseline patient characteristics.
Patient Characteristics NTCD n=54
TCD 
n=95 P
Median age (years/range) 48 (20-63)
50 
(17-69) .32 
Sex (%)
   Male 63 (34) 63.2 (60)
1.0 
   Female 37 (20) 36.8 (35)
Disease (%)
   Acute leukemia/MDS 64.8 (35) 55.7 (53) .30
   Non-Hodgkin lymphoma 7.4   (4) 23.2 (22) .01
   Hodgkin lymphoma 3.7   (2) 3.2   (3) 1.0
   Chronic myeloid 
   leukemia 22.2 (12) 6.3   (6) .007
   Chronic lymphoid 
   leukemia 1.8   (1) 3.1   (3) 1.0
   Multiple myeloma 0 3.2   (3) .55
   Othersa 0 5.2   (5) .16
Risk groupb (%)
   Standard risk 38.9 (21) 13.7 (13)
<.01
   High risk 61.1 (33) 86.3 (82)
Conditioning regimen (%)
   Myeloablative 83.3 (45) 72.6 (69)
.17   Reduced intensity / 
   non-myeloablative 16.7 (9) 27.4 (26)
Donor/matchc (%)
   Sibling HLA-identical 68.5 (37) 37.9 (36) <.01
   URD HLA-identical 24.1 (13) 48.4 (46) <.01
   HLA-mismatched 7.4   (4) 13.7 (13) .29
GVHD prophylaxis (%)
   Tacrolimus-based 31.5 (17) 66.3 (63)
<.01
   Cyclosporine-based 68.5 (37) 33.7 (32)
NTCD: non T-cell depleted, TCD: T-cell depleted, MDS: myelodysplastic syndrome, 
URD: unrelated donor, HLA: human leukocyte antigen, GVHD: graft versus host disease. 
P values were calculated using the Fisher exact test for categorical variables and 
using the t test for continuous variables. aAplastic anemia (n=4) and myelofibrosis 
(n=1). bStandard risk includes refractory anemia, refractory anemia with ringed 
sideroblasts, acute leukemia in 1st complete remission and CML in chronic phase (all 
others high risk). cHigh-resolution allele level matching for HLA -A, -B, -C, and -DRB1.
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CD8+ cell doses and neutrophil recovery (Table 3). 
In the NTCD group, univariate analysis did not show 
any association between cell doses and neutrophil en-
graftment.
For the evaluation of platelet recovery, 14 patients 
did not recover their counts and 19 patients had a nadir 
above 20×109/L. Median time to platelet recovery was 
18 days in both groups, (mean NTCD group 22 days, 
95%CI, 18.5-25.4 and mean TCD group 21.8 days, 
95%CI 18.4-25.3, P=.95). Univariate analysis was 
suggestive of earlier platelet engraftment in the TCD 
group with higher (>50th centile) doses of CD3+, 
CD4+ and CD8+ cell doses (Table 3). However, mul-
tivariate analysis showed no association between plate-
let recovery and higher infused cell doses for CD3+ 
(P=.62), CD4+ (P=.29) and CD8+ (P=.68) in the 
TCD group.
Seven patients who were deemed to have primary 
graft failure were excluded in the acute GVHD analy-
sis. The incidence of grade II-IV acute GVHD in 
the NTCD and TCD groups was 51.9% (n=27) and 
44.4% (n=40) respectively (RR=0.87, 95% CI=0.62-
1.21; P=.49). The incidence of grade III-IV acute 
GVHD in the NTCD and TCD groups was 19.2% 
(n=10) and 18.9% (n=17) respectively (RR = 0.99, 
95% CI = 0.84-1.18; P=1.0). Univariate analysis did 
not show any significant association between CD34+, 
CD3+, CD4+ and CD8+ cell doses and rates of grade 
II-IV and grade III-IV acute GVHD, precluding a 
multivariate analysis (Table 4). 
One hundred and twenty patients who survived 
until 100 days post-transplant were considered eligi-
ble for the analysis. The incidence of chronic GVHD 
in the NTCD and TCD groups was 55.6% (n=25) 
and 52% (n=39) respectively (RR 1.07, 95%CI 0.76-
1.50, P=.85). Rates of extensive chronic GVHD in 
the NTCD and TCD group was 46.7% (n=21) and 
36% (n=27) respectively (RR 1.29, 95%CI 0.84-2.0, 
P=.26). On univariate analysis (Table 4) no correla-
tion was seen in the incidence of chronic GVHD and 
cell doses in the TCD group. In the NTCD group no 
association existed between CD3+, CD4+ and CD8+ 
cell doses and chronic GVHD and extensive chronic 
GVHD, but an increased incidence of chronic GVHD 
was noted with lower CD34+ cell doses; 70.4% (n=19) 
vs. 33.3% (n=6), (RR 0.47, 95% CI 0.24-0.95, P=.03). 
Univariate analysis also showed a trend towards in-
creased extensive chronic GVHD with lower CD34+ 
cell dose in the NTCD group; 59.2% (n=16) vs. 27.8% 
(n=5) (RR 0.47, 95%CI 0.21-1.10, P=.06). A multi-
variate model was not constructed because no signifi-
cance was noted with any other cell subtype.
Median follow-up for surviving patients was 3 
years (1071 days, range: 146-2394 days). The OS in 
the NTCD and TCD groups at 1 year was 51.8% 
and 54.7%, respectively, and at 3 years was 38.4% and 
Table 2. Median cell doses in NTCD and TCD groups.
Cell doses 
(per kg patient 
weight)
NTCD median 
(range)
TCD median 
(range) P
CD34+×106 5.4 (1.2-12.9) 6.2 (1.9-16) .008
CD3+×107 29.6 (5.7-44.7) 31.1 (4.5-100.8) .91
CD4+×107 18.7 (4.6-44.7) 18.6 (1.9-63) .80
CD8+×107 10.6 (0.8-52.4) 11.6 (2.1-44.7) .9
NTCD: non T-cell depleted, TCD: T-cell depleted. P value estimated using t test.
Table 3. Univariate analysis showing effects of higher and lower cell doses in NTCD and 
TCD groups on neutrophil and platelet engraftment.
Days to 
neutrophil 
engraftment
NTCD group 
(95% CI) [P]
TCD group 
(95% CI) [P]
  CD34+
<50th centile 16.3 (15.0-17.7)        [.18]
16.8 (15.6-18.0)     
[.08]
>50th centile 14.9 (13.2-16.6) 15.4 (14.4-16.4)
  CD3+
<50th centile 15.9 (14.1-17.4)        [.95]
16.1 (14.9-17.3)     
[.73] 
>50th centile 15.8 (14.4-17.3) 15.8 (14.8-16.9)
  CD4+
<50th centile 15.3 (13.8-16.9)        [.37] 
16.0 (14.9-17.0)     
[1.0]
>50th centile 16.3 (14.8-17.8) 16.0 (14.9-17.0)
  CD8+
<50th centile 15.7 (14.4-17.6)        [.82]
16.2 (15.1-17.3)
[.5]
>50th centile 16.0 (14.2-17.2) 15.7 (14.7-16.8)
Days to 
platelet 
engraftment
  CD34+ 
<50th centile 23.2 (18.9-27.5)        [.35]
23.1 (17.7-28.5)     
[.55]
>50th centile 19.8 (14.1-25.6) 20.9 (16.5-25.4) 
  CD3+
<50th centile 22.0 (17.5-26.5)        [.96]
26.5 (21.6-31.5)     
[.013]
>50th centile 21.9 (16.4-27.3) 18.0 (13.6-22.5)
  CD4+
<50th centile 21.6 (16.9-26.3)        [.82] 
26.2 (21.5-30.8)     
[.01]
>50th centile 22.4 (17.3-27.6) 17.5 (12.9-22.2)
  CD8+
<50th centile 22.6 (17.9-27.3)        [.71]
25.2 (20.4-30.0)     
[.05]
>50th centile 21.3 (16.1-26.4) 18.6 (13.9-23.3) 
NTCD: non T-cell depleted, TCD: T-cell depleted. P values estimated using t test. 
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39.7%, respectively (log-rank P=.86). Univariate anal-
ysis showed a significant association between CD34+, 
CD3+ and CD8+ cell doses and OS in the TCD 
group (Table 5). 
On multivariate regression analysis, only CD34+ cell 
dose >5.8×106/kg PW (median) was associated with 
improved OS (RR=0.58, 95% CI=0.34-0.98, P=.04) 
in the TCD group (Figure 1). Higher CD3+ cell dose, 
>30.8×107/kg PW, showed a trend towards improved 
OS (RR= 0.54, 95% CI=0.29-1.01, P=.053). 
The PFS in the NTCD and TCD groups at 1 
year was 46.2% and 45.1% respectively and at 3 years 
was 28.9% and 34.2% respectively (log-rank P=.7). 
Univariate analysis showed a significant association 
with higher CD34+, CD3+, CD4+ and CD8+ cell 
doses and PFS in the TCD group; P<.1 (Table 5). 
However, multivariate analysis suggested improved 
PFS with higher CD34+ cell doses only (RR 0.59, 
95% CI=0.35-1.00, P=.05). The 1-year cumulative in-
cidence of NRM in the NTCD and TCD groups was 
30% and 25%, respectively, and at 3 years it was 35% 
and 32%, respectively (Gray test P=.64). By univariate 
analysis, in the TCD group higher CD34+, CD3+ and 
CD8+ cell doses was associated with improved NRM 
(Table 5). In multivariate analysis statistical signifi-
cance was seen only with CD34+ cell dose >5.8×106/
kg PW, (RR 0.49, 95%CI 0.24-0.99, P=.048). Relapse 
in the NTCD and TCD groups at 1 year was 26% 
and 31% respectively, and at 3 years was 35% for both 
groups, P=.95. By univariate analysis there was no dif-
ference in relapse rates between the NTCD and TCD 
groups stratified by cell doses (P>.1). 
DISCUSSION
In this study, we analyzed the effects of cellular graft 
composition on transplantation outcomes of patients 
receiving either T-cell replete or T-cell depleted pe-
ripheral blood AHCT. Interesting observations were 
made in patients undergoing AHCT with in vivo 
Table 4. Univariate analysis comparing the incidence of grades 
II-IV and III-IV acute graft versus host disease (GVHD) and 
chronic and extensive chronic GVHD by cell doses (< and > 50th 
percentile) in the non T-cell depleted (NTCD) and T-cell depleted 
(TCD) groups.
Grade II-IV 
acute GVHD
NTCD group
RR (95% CI); [P]
TCD group
RR (95% CI); [P]
  CD34+ 1.44 (0.74-2.82); [.40]  0.93 (0.66-1.33); [.83]
  CD3+ 0.67 (0.35-1.26); [.26]  0.97 (0.68-1.40); [1.00]
  CD4+ 0.72 (0.44-1.32); [.41]  1.08 (0.72-1.61); [.83]
  CD8+ 0.74 (0.41-1.35); [.40]  1.16 (0.79-1.71); [.52]
Grade III-IV 
acute GVHD
  CD34+ 0.60 (0.31-1.14); [.28]  1.28 (0.75-2.19); [.42]
  CD3+ 1.43 (0.54-3.79); [.49]  1.25 (0.73-2.15); [.42]
  CD4+ 1.18 (0.54-2.58); [.73]  1.14 (0.66-1.96); [.79]
  CD8+ 1.07 (0.48-2.38); [1.00]  1.67 (0.85-3.27); [.11]
Chronic 
GVHD
  CD34+ 0.47 (0.24-0.95) [.03] 1.13 (0.72-1.77) [.64]
  CD3+ 1.02 (0.59-1.74) [1.0] 1.41 (0.87-2.28) [.17]
  CD4+ 0.91 (0.53-1.56) [.77] 0.97 (0.63-1.50) [1.0]
  CD8+ 1.17 (0.67-2.03) [.76] 0.97 (0.62-1.49) [1.0]
Extensive 
chronic 
GVHD
  CD34+ 0.47 (0.21-1.10) [.06] 0.88 (0.48-1.61) [.81]
  CD3+ 1.47 (0.76-2.81) [.36] 1.67 (0.84-3.32) [.15]
  CD4+ 1.37 (0.70-2.68) [.38] 1.15 (0.63-2.12) [.81]
  CD8+ 0.98 (0.51-1.88) [1.0] 1.21 (0.65-2.24) [.63]
RR: relative risk, CI: confidence interval. P values estimated using the Fisher exact test.
Table 5. Univariate analysis showing overall survival, progression 
free survival and non-relapse mortality in non T-cell depleted 
(NTCD) and T-cell depleted (TCD) group, illustrating the impact of 
higher cell doses (> 50th percentile).
Overall 
survival
NTCD group
RR (95% CI); [P]
TCD group
RR (95% CI); [P]
  CD34+ 0.96 (0.48-1.85) [.91] 0.63 (0.38-1.04) [.07]
  CD3+ 0.98 (0.50-1.90) [.95] 0.52 (0.31-0.87) [.01]
  CD4+ 1.38 (0.71-2.72) [.34] 0.66 (0.39-1.1)   [.12]
  CD8+ 0.84 (0.43-1.62) [.61] 0.54 (0.32-0.9)   [.02]
Progression 
free survival
  CD34+ 1.07 (0.56-2.00) [.83] 0.64 (0.39-1.06) [.08]
  CD3+ 0.97 (0.51-1.81) [.91] 0.56 (0.34-0.92) [.02]
  CD4+ 1.27 (0.68-2.43) [.45] 0.63 (0.36-1.04) [.07]
  CD8+ 0.91 (0.48-1.69) [.76] 0.60 (0.36-0.98) [.04]
Non relapse 
mortality
  CD34+ 0.73 (0.28-1.73) [.49] 0.49 (0.24-0.99) [.04]
  CD3+ 1.44 (0.61-3.53) [.41] 0.51 (0.25-1.01) [.05]
  CD4+ 1.56 (0.66 – 3.94) [.33] 0.66 (0.33-1.31) [.24]
  CD8+ 0.93 (0.39-2.23) [.96] 0.42 (0.20-0.85) [.04]
RR: relative risk, CI: confidence interval. P values calculated using log-rank test.
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Figure 1. Kaplan-Meir estimate of overall survival and progression free survival by 
CD34+ cell doses in the T-cell depleted (TCD) group. The bold line represents CD34+ 
cell dose >50th centile and the broken line represents <50th centile; median cell dose = 
5.8×106/kg patient weight (PW). A. OS: risk ratio 0.58, 95% confidence interval 0.34-0.98; 
log-rank P=.04. B. PFS: risk ratio 0.59, 95% confidence interval 0.35-1.00; P=.05.
T-cell depletion (TCD group). Multivariate analysis 
showed that higher CD34+ cell dose (>5.8×106/kg 
PW) improved OS, PFS and NRM, but had no im-
pact on disease relapse. Although there was no associa-
tion between infused cell doses and engraftment kinet-
ics in multivariate analysis, univariate analysis showed 
early neutrophil engraftment with higher CD34+ cell 
dose. Univariate analysis was suggestive of better plate-
let engraftment with higher CD3+, CD4+ and CD8+ 
cell doses in the TCD group without any impact from 
the CD34+ cell dose.
Great interest exists in understanding the effects 
of cellular allograft composition on clinical outcomes 
of patients undergoing AHCT. The ideal CD34+ cell 
dose infused to optimize survival outcomes of periph-
eral blood AHCT remains a matter of controversy. 
While some studies have not reported any impact on 
survival with higher infused CD34+ cell doses,10,29 
others have shown improved OS with higher CD34+ 
cell doses in URD peripheral blood AHCT.5,8 Collins 
et al have suggested improved OS following periph-
eral blood URD transplantation in patients receiving 
CD34+ cell doses >5×106/kg.8 Similarly, Pulsifer et al 
have shown improved OS with URD peripheral blood 
transplantation with CD34+ cell doses between 4.5-
9.5×106/kg.5 Interestingly this beneficial effect was 
lost in patients receiving doses greater than 9.5×106/
kg. These findings underscore the need to better define 
the optimal CD34+ dose for patients receiving periph-
eral blood allografts.
The optimal infused CD34+ cell dose for patient 
receiving in vivo TCD allografts is even more contro-
versial, with no data (to our knowledge) assessing the 
relative importance of infused doses in T-cell replete 
versus T-cell depleted setting. Kalwak et al reported 
improved OS and disease-free survival in pediatric pa-
tient population with CD34+ cell dose >10×106/kg, 
specifically with in vivo TCD as GVHD prophylaxis.15 
In contrast Tsirigotis et al, in a study which included 
both adult and pediatric patients receiving ATG as part 
of transplant conditioning reported no effect on OS of 
CD34+ doses >10×106/kg. This observation is in line 
with the finding from Pulsifer et al where CD34+ cell 
doses greater than 9.5×106/kg had no beneficial effect 
on survival outcomes.5 Interestingly, in our study the 
benefit of higher CD 34+ cells doses (doses >5.8×106/
kg PW) in terms of improved OS, PFS and NRM was 
restricted to patients receiving TCD allografts. The 
survival benefit in the TCD group with higher CD34+ 
cell dose may be due to a more robust immune recon-
stitution leading to decreased NRM rates. 
Our data did not show any difference in relapse 
rates between the NTCD and TCD group and no sta-
tistically significant association with CD34+, CD3+, 
CD4+ and CD8+ cell doses, which is contrast with 
previous reports showing decreased relapse rates with 
higher infused CD34+ cell dose.9,29 Lower NRM seen 
in the TCD group with higher CD34+ cell doses seen 
in our study has been reported in patients undergoing 
NTCD transplants.5 
Our analysis did not show any difference between 
the TCD and NTCD groups with regards to neutro-
phil engraftment and platelet recovery in the multivari-
ate model. It must be noted however that univariate 
analysis suggested faster neutrophil engraftment with 
higher CD34+ cell doses. Interestingly, in the TCD 
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group univariate analysis was also suggestive of faster 
platelet recovery with a higher T-cell dose. A prior 
study has also shown early platelet engraftment with 
higher CD8+ (>8×107/kg) cell doses without affect-
ing neutrophil recovery.8 
The association between cell doses, CD34+ in par-
ticular and incidence of GVHD has been controver-
sial. Several studies have shown increased incidence of 
acute and chronic GVHD with higher CD34+ cell 
doses.4,9,11,12 An explanation for this interesting find-
ing remains a mystery. In an elegant study, Reisner 
et al showed that donor CD34+ cells can act as ‘veto’ 
cells and may suppress host T-cells capable of donor 
alloreactivity. Thus, theoretically, infusion of large 
numbers of donor CD34+ cells can eliminate ‘host-
versus-graft’ reaction, turning the balance in favor of 
the ‘graft-versus-host’ reaction, leading to increased 
incidence of GVHD.30,31 In our study, we did not see 
any association between CD34+ cell dose and acute 
GVHD in the NTCD and TCD groups. These re-
sults are in concordance with several recent reports. 
There was no association between incidence of chron-
ic GVHD to CD34+, CD3+, CD4+ and CD8+ cell 
doses in the TCD group, while in the NTCD group; 
lower infused CD34+ cell dose was associated with 
increased chronic extensive GVHD, contrary of pre-
vious reports.4,9 This finding is indeed perplexing and 
we have no satisfactory explanation for it. It is likely 
due to the nature of the analysis (retrospective), and 
the low number of patients.
The rates of acute GVHD in the TCD group in 
our study appear to be higher than the recent report by 
Socie et al.32 However it is important to point out that 
majority of patients in our study received TCD with 
Thymoglobulin, unlike Socie et al’s study were ATG-
Fresenius was employed. Our acute GVHD rates in fact 
are very similar to a recent CIBMTR study, where rates 
of grade II-IV acute GVHD in the Thymoglobulin 
group was 38%.33 Moreover a significant proportion of 
TCD group patients were also HLA mismatched with 
their donors, further explaining the incidence of acute 
GVHD in our study. In a prospective study Bacigalupo 
et al, patients receiving ATG doses of 7.5 mg/kg had 
grade III-IV acute GVHD rates of 36%. The ATG 
dose used in our study was lower (6 mg/kg), which 
is another likely explanation of slightly higher acute 
GVHD rates in our experience.34 
Similarly the disparities noted between our study 
and the report by Socie et al in terms of rates of chronic 
GVHD are likely reflective of various ATG prepara-
tions used in these studies (Thymoglobulin vs. ATG-
Fresenius) with differing biological activities, diver-
gent biologically active doses, different administration 
schedules, differences ntensity of conditioning regimens 
(as indicated in CIBMTR data) and the degree of pa-
tient/donor HLA match in the two studies studies.32,33 
The relevance of such biological differences between 
various ATG types has been recently reviewed.35
Our retrospective analysis is limited by the het-
erogeneity of the patient population, with the TCD 
group having more high-risk patients and URD trans-
plants. Acknowledging these limitations, our report 
is suggestive of improved survival and NRM with 
higher CD34+ cell doses without increasing the risk 
of GVHD and relapse, in patients undergoing in vivo 
T-cell depleted AHCT. The improved OS seen with 
higher CD34+ cell dose (>5.8×106/kg PW) in TCD 
transplants is likely due to improved rates of NRM. 
We hypothesize that the improved NRM and OS in 
TCD transplant might be due to a more robust im-
mune reconstitution with higher cell doses thereby 
reducing infectious complication otherwise associated 
with TCD. 
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